| Date | Title | Description |
| 21.05.2025 | Nanobiotix Provides First Quarter 2025 Operational and Financial Update | Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancer Presentation of data at the European Lung Cancer Conference in a Phase 1 study... |
| 21.05.2025 | Nanobiotix fait le point sur sa trésorerie et son activité opérationnelle du premier trimestre 2025 | Traitement du premier patient dans l’étude CONVERGE, un essai clinique contrôlé randomisé de Phase 2 chez des patients atteints d’un cancer du poumon non à petites cellules (CPNPC) non résécable de stade 3. Présentation de données à l’ELCC ... |
| 31.03.2025 | NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 | PARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibili... |
| 27.03.2025 | Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC | Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failed
A preliminary review of survival data showed 12-month LPFS of 64%... |
| 27.03.2025 | Nanobiotix annonce les premières données issues de la partie escalade de dose completée d’une étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d’un CPNPC loc... | Les données montrent un profil de sécurité favorable et confirment la faisabilité de l’injection chez 12 patients atteints d’un cancer du poumon (CPNPC) localement avancé éligibles à une ré-irradiation et pour lesquels les lignes de traitem... |
| 27.03.2025 | Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC | Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failed
A preliminary review of survival data showed 12-month LPFS of 64%... |
| 20.03.2025 | NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference | Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable, locoregional recurrent NSCL... |
| 13.03.2025 | Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social | Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers
PARIS, 13 mars 2025 (GLOBE NEWSWIRE) --
Paris, France, le 13 mars 2025
Place de cotation : Euronext Paris / Nasdaq
... |
| 13.03.2025 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, March 13, 2025 (GLOBE NEWSWIRE) --
Paris, France, M... |
| 13.03.2025 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, March 13, 2025 (GLOBE NEWSWIRE) --
Paris, France, M... |
| 09.01.2025 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Jan. 09, 2025 (GLOBE NEWSWIRE) --
Paris, France, Ja... |
| 09.01.2025 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Jan. 09, 2025 (GLOBE NEWSWIRE) --
Paris, France, Ja... |
| 09.01.2025 | Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social | Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général
de l’Autorité des Marchés Financiers
PARIS, 09 janv. 2025 (GLOBE NEWSWIRE) --
Paris, France, le 9 janvier 2025
Place de cotation : Euronext Paris / Nasd... |
| 11.12.2024 | Voting Rights and Shares Capital of the Company | In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Dec. 11, 2024 (GLOBE NEWSWIRE) --
Paris, France, De... |
| 12.11.2024 | NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms | Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submission Added expert industry leaders to Supervisory Board, further strengthening support ... |
| 12.11.2024 | NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms | Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory Board, further strengthening support f... |
| 31.10.2024 | NANOBIOTIX to Participate in Multiple Investor Conferences in November | ~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~
~ Stifel Healthcare Conference, Nov 18-19 ~
~ Jefferies London Healthcare Conference, Nov 19-21 ~
PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTI... |
| 11.10.2024 | Voting Rights and Shares Capital of the Company | In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Oct. 11, 2024 (GLOBE NEWSWIRE) --
Paris, France, Oc... |
| 11.10.2024 | Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social | Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers
PARIS, 11 oct. 2024 (GLOBE NEWSWIRE) --
Paris, France, le 11 octobre 2024
Place de cotation : Euronext Paris / Nasd... |
| 11.10.2024 | Voting Rights and Shares Capital of the Company | In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Oct. 11, 2024 (GLOBE NEWSWIRE) --
Paris, France, Oc... |
| 18.09.2024 | NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results | RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune system before checkpoint therapySeveral... |
| 04.09.2024 | NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth | Dr. Margaret A. Liu, global expert in vaccines, gene therapy, and cancer immunotherapy; chief executive officer of PAX Therapeutics and member of several boards
Ms. Anat Naschitz, proven life science investor and entrepreneur; co-founder of... |
| 09.07.2024 | Voting Rights and Shares Capital of the Company | In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, July 09, 2024 (GLOBE NEWSWIRE) --
Market: Euronext ... |
| 09.07.2024 | Voting Rights and Shares Capital of the Company | In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, July 09, 2024 (GLOBE NEWSWIRE) --
Market: Euronext ... |
| 09.07.2024 | Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social | Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers
PARIS, 09 juill. 2024 (GLOBE NEWSWIRE) --
Place de cotation : Euronext Paris / Nasdaq
Euronext Compartiment : B
Cod... |
| 02.06.2024 | Nanobiotix annonce de nouvelles données montrant un contrôle de la maladie et une réponse tumorale chez des patients traités avec NBTXR3 activé par radiothérapie suivi d’un anti-PD-1, comme traitement... | Traitement faisable et bien toléré chez 68 patients fortement prétraités atteints de CETEC-R/M (population en intention de traiter, ITT) qui ont reçu NBTXR3 activé par radiothérapie suivi d’un anti-PD-1 comme traitement de deuxième intentio... |
| 14.05.2024 | NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament, la FDA, d'un protocole pour une nouvelle étude randomisée de Phase 2 évaluant NBTXR3 pour les patients atteints d'un cancer du p... | PARIS et CAMBRIDGE, Mass., 14 mai 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur la... |
| 14.05.2024 | NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer | PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment... |
| 10.04.2024 | Voting Rights and Shares Capital of the Company | In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, April 10, 2024 (GLOBE NEWSWIRE) --
Market: Euronext... |
| 10.04.2024 | Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social | Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers
PARIS, 10 avr. 2024 (GLOBE NEWSWIRE) --
Place de cotation : Euronext Paris / Nasdaq
Euronext Compartiment : B
Code ... |
| 06.03.2024 | Nanobiotix to Present at Upcoming Investor Conferences in March | - |
| 31.01.2024 | Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference | PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities f... |
| 31.01.2024 | Nanobiotix participera à la 6ème conférence annuelle de Biotechnologie de Guggenheim | PARIS and CAMBRIDGE, Mass., 31 janv. 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur... |
| 11.01.2024 | Voting Rights and Shares Capital of the Company | In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Jan. 11, 2024 (GLOBE NEWSWIRE) --
Market: Euronext ... |
| 11.01.2024 | INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL | Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers
PARIS, 11 janv. 2024 (GLOBE NEWSWIRE) --
Place de cotation : Euronext Paris / Nasdaq Euronext Compartiment : B
Code... |
| 04.12.2023 | Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc. | - |
| 02.11.2023 | NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M | - |
| 20.07.2023 | Voting Rights and Shares Capital of the Company | /EIN News/ -- In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, July 20, 2023 (GLOBE NEWSWIRE) --
Mar... |
| 08.06.2023 | Voting Rights and Shares Capital of the Company | /EIN News/ -- In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, June 08, 2023 (GLOBE NEWSWIRE) --
Mar... |
| 17.04.2023 | NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023 | /EIN News/ -- Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April 25, 2023
PARIS and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-stage clin... |
| 11.01.2023 | Voting Rights and Shares Capital of the Company | In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
/EIN News/ -- PARIS, Jan. 11, 2023 (GLOBE NEWSWIRE) --
Mar... |
| 10.11.2022 | NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of C... | Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST Data show that radiotherapy-activated NBTXR3 followed by anti-PD-1 was feasible and well tolerated in the complete dose escalation part of the Company’s phase 1 immunothe... |
| 31.10.2022 | NANOBIOTIX to Present at the Jefferies London Healthcare Conference | /EIN News/ -- PARIS and Cambridge, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment ... |
| 27.10.2022 | NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022 | PARIS and CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities f... |
| 27.10.2022 | NANOBIOTIX annoncera le 9 novembre 2022, ses resultats financiers pour le troisieme trimestre 2022 | PARIS et CAMBRIDGE, Mass., 27 oct. 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur la physique ... |
| 18.10.2022 | NANOBIOTIX conclut un accord définitif pour la restructuration du prêt octroyé par la Banque européenne d’investissement | PARIS et CAMBRIDGE, Mass., 18 oct. 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX - la « Société »), société de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur la physique... |
| 18.10.2022 | NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank | PARIS and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities f... |
| 10.01.2022 | NANOBIOTIX : Provides Corporate Update and Highlights Key 2022 Milestone Targets - Form 6-K | NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized in global phase III NAN... |
| 20.05.2021 | NANOBIOTIX
Nanobiotix : Announces Updated Results From Priority Pathways In Head And Neck Cancer And Immunotherapy For Potential First-In-Class Radioenhancer NBTXR3 At 2021 Annual Meeting Of The Amer... | PRESS RELEASE
NANOBIOTIX ANNOUNCES UPDATED RESULTS FROM PRIORITY PATHWAYS IN HEAD AND NECK CANCER AND IMMUNOTHERAPY FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 AT 2021 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL ONCOLOGY
Updat... |
| 29.04.2021 | Nanobiotix : Rapport sur les comptes annuels - AGM 2021 | GRANT THORNTON ERNST & YOUNG et Autres
French member of Grant Thornton International
This is a translation into English of the statutory auditors' report on the financial statements of the Company issued in French and it is provided sol... |
| 12.04.2021 | NANOBIOTIX
Nanobiotix : Depositary's Notice of Combined General Meeting of Nanobiotix S.A. - AGM 2021 | Time Sensitive
Materials
Depositary's Notice of
Combined General Meeting
of
Nanobiotix S.A.
ADSs: American Depositary Shares.
ADS CUSIP No.: 63009J107.
ADS Record Date: March 26, 2021.
Date to determine ADS Holders who are to receive these ... |
| 12.04.2021 | NANOBIOTIX
Nanobiotix : Voting Instruction - AGM 2021 | Combined General Meeting
The Voting Instructions must be signed, completed and received at the indicated address prior to
10:00 A.M. (New York City time) on April 22, 2021 for action to be taken.
2021 VOTING INSTRUCTIONS AMERICAN DEPOSITARY... |
| 08.04.2021 | Nanobiotix : Amendment to Annual Report by Foreign Issuer (SEC Filing - 20-F/A) | nbx-20201231
____________________________________________________________________________________________________________________________________________________________________________________________
UNITED STATES
SECURITIES AND EXCHANGE ... |
| 08.04.2021 | NANOBIOTIX
Nanobiotix : Amendment to Annual Report by Foreign Issuer (SEC Filing - 20-F/A) | nbx-20201231
____________________________________________________________________________________________________________________________________________________________________________________________
UNITED STATES
SECURITIES AND EXCHANGE ... |
| 07.04.2021 | Nanobiotix : Rapport sur les comptes annuels - AGM 2021 | GRANT THORNTON ERNST & YOUNG et Autres
French member of Grant Thornton International
This is a translation into English of the statutory auditors' report on the financial statements of the Company issued in French and it is provided sol... |
| 07.04.2021 | Nanobiotix : Rapport sur les comptes consolidés - AGM 2021 | GRANT THORNTON ERNST & YOUNG et Autres
French member of Grant Thornton International
This is a translation into English of the statutory auditors' report on the consolidated financial statements of the Company issued in French and it is... |
| 11.12.2020 | Nanobiotix : Audit committee charter and internal rules of procedure | NANOBIOTIX
AUDIT COMMITTEE
CHARTER
AND
INTERNAL RULES OF PROCEDURE
With the approval of the supervisory board of the Company (the "Board"), the audit committee of Nanobiotix (the "Company") adopted this Charter and Inter... |
| 11.12.2020 | NANOBIOTIX
Nanobiotix : Audit committee charter and internal rules of procedure | NANOBIOTIX
AUDIT COMMITTEE
CHARTER
AND
INTERNAL RULES OF PROCEDURE
With the approval of the supervisory board of the Company (the "Board"), the audit committee of Nanobiotix (the "Company") adopted this Charter and Inter... |
| 23.10.2020 | NANOBIOTIX
Nanobiotix : announces third quarter 2020 revenue | PRESS RELEASE
NANOBIOTIX ANNOUNCES THIRD QUARTER 2020 REVENUE
Paris, France; Cambridge, Massachusetts (USA); October 23, 2020 - NANOBIOTIX(Euronext : NANO - ISIN : FR0011341205 - the ''Company''), a late clinical-stage nanomedicine company ... |
| 28.07.2020 | NANOBIOTIX
Nanobiotix : Successfully Raises Approximately 20 (us$24) Million in Placement of Ordinary New Shares With Us and European Investors | Regulatory News:
Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purposes only.
NANOBIOT... |
| 28.07.2020 | NANOBIOTIX
Nanobiotix : successfully raises approximatively 20 million in placement of ordinary new shares with US and european investors | PRESS RELEASE
NANOBIOTIX SUCCESSFULLY RAISES APPROXIMATELY €20 (US$24) MILLION IN PLACEMENT OF ORDINARY NEW SHARES WITH US AND EUROPEAN INVESTORS
Funds raised through an accelerated bookbuild offering announced on July 27, 2020
Crossover ro... |
| 27.07.2020 | NANOBIOTIX
Nanobiotix : raises approximately EUR 29.5 million in placement of ordinary new shares | Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia
or Japan. This press release is not intended as an offer and is for informational purposes only.
NANOBIOTIX RAISES APPROXI... |
| 08.06.2020 | Nanobiotix Secures €10M in Non-Dilutive Financing | PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has received financing approval from HSBC and Bpifra... |
| 16.10.2018 | Nanobiotix Receives First Tranche Disbursement of 16 Million Euros Financing from European Investment Bank | ARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company r... |
| 22.06.2018 | Nanobiotix shares rocket up on a marginal success for soft tissue sarcoma; AstraZeneca wins pioneering PD-L1 OK in India | → Shares of Nanobiotix (Euronext: NANO) soared after the biotech reported positive though marginal results for its Phase II/III study of NBTXR3 in soft tissue sarcoma. But the key outcome was not great. Nanobiotix reported ... |
| 06.07.2017 | Nanobiotix leverages physics to fight cancer | The 50-nanometer particles (50 billionths of a meter) are injected directly into tumors and absorbed by cancer cells. From there, they multiply the radiation’s ability to liberate electrons from water molecules, generate free radicals and h... |
| 13.12.2012 | Brainloop supports Major Licensing Deal for Nanobiotix with its Secure Dataroom | Munich, Germany, 13 December 2012 – Brainloop announced today that French Nanobiotix S.A., a leader in the development of cancer treatments based on nanotherapeutics, has used Brainloop’s Secure Dataroom to negotiate an exclusive licensing ... |
| 03.05.2012 | Nanotherapeutic targets tumors in lung cancer patients, saves healthy cells | Nanobiotix’s lead nanoXray therapeutic, NBTXR3, is injected into the tumor or the region of it and activated by radiation therapy. The nanoparticles are designed to strategically destroy tumors in soft tissue sarcoma patients by accumulatin... |
| 03.05.2010 | Nanobiotix Raises $11M in Series C Financing Round | Nanobiotix, a Paris, France-based company wich develops innovative therapeutic products for cancer using nanotechnologies, closed a $11m Series C financing round.
The round was led by CIC Vizille Capital Innovation, with participation from ... |
| - | Nanotherapeutic targets tumors in lung cancer patients, saves healthy cells | A French nanomedicine company developing a novel cancer therapeutic to strategically destroy tumors in lung cancer patients to improve survival rates has forged a research collaboration with an East Coast hospital.
Nanobiotix’s two-year res... |
| - | Nanobiotix leverages physics to fight cancer | Radiation kills cancer cells, but it also takes healthy cells with them. The problem puts radiation oncologists in a bind – higher doses could cure more patients but the collateral damage would put them at greater risk. Paris-based Nanobiot... |
